NCT06439589View on ClinicalTrials.gov

Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

June 12, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Solid Tumors
Interventions
DRUG

HRS2398

HRS2398: Tablets, 40mg/tablet, oral

DRUG

Adebrelimab

Adebrelimab (SHR-1316): injection, 600mg(12mL), intravenous infusion

Trial Locations (2)

200030

NOT_YET_RECRUITING

Shanghai Chest Hospital, Shanghai

450003

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY